Last reviewed · How we verify
Atomoxetine and OROS Methylphenidate
This is a combination of two norepinephrine-enhancing medications: atomoxetine (a selective norepinephrine reuptake inhibitor) and OROS methylphenidate (an extended-release stimulant that increases dopamine and norepinephrine).
This is a combination of two norepinephrine-enhancing medications: atomoxetine (a selective norepinephrine reuptake inhibitor) and OROS methylphenidate (an extended-release stimulant that increases dopamine and norepinephrine). Used for Attention-deficit/hyperactivity disorder (ADHD).
At a glance
| Generic name | Atomoxetine and OROS Methylphenidate |
|---|---|
| Also known as | Strattera, Concerta |
| Sponsor | Massachusetts General Hospital |
| Drug class | Norepinephrine reuptake inhibitor + stimulant combination |
| Target | Norepinephrine transporter (NET); dopamine transporter (DAT) and norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Atomoxetine selectively inhibits the norepinephrine transporter, increasing norepinephrine availability in the prefrontal cortex and improving attention and executive function. OROS methylphenidate is a long-acting formulation that blocks dopamine and norepinephrine reuptake, providing sustained symptom control throughout the day. The combination targets complementary pathways to enhance attention and reduce impulsivity and hyperactivity.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
Common side effects
- Insomnia
- Headache
- Nausea
- Decreased appetite
- Increased heart rate
- Elevated blood pressure
- Anxiety
Key clinical trials
- Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
- Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits (PHASE2)
- Effects of Atx and Oros-mph on Executive Functions (PHASE4)
- A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE2)
- A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents (PHASE4)
- Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD (PHASE4)
- Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children (PHASE4)
- Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: